Insights - Lexicon Pharmaceuticals (LXRX) will partner with JDRF (Juvenile Diabetes Research Foundation) for a phase 2 study of LX4211 in younger Type 1 Diabetes (T1D) patients (<30 … Continue Reading
Read nowInsights - Celgene (CELG) said on Wednesday morning that a phase 3 trial of Otezla, the company’s oral inhibitor of phosphodiesterase 4 (PDE4) already approved in active psoriatic … Continue Reading
Read nowInsights - Anacor (ANAC) received FDA approval for the antifungal Kerydin on Tuesday, setting it and the larger Valeant (VRX) up for a marketing battle.
Read nowInsights - Following an end-of-phase 2 meeting with the FDA, Synergy Pharmaceuticals (SGYP) will begin two phase 3 studies of plecanatide, the company’s lead drug candidate, in Irritable … Continue Reading
Read nowInsights - Since Mr. Deryugin suggested in December that BioDelivery Sciences (BDSI) would be delivering profits in 2014, this pick is up 175%.
Read nowRecap - It was a shortened trading week in the U.S. with markets closed the entirety of Friday and half of Thursday, though activity and volatility in the healthcare … Continue Reading
Read nowInsights - Shares of Regado Biosciences (RGDO) fell 50% after the company reported an unplanned review of the ongoing REGULATE-PCI phase 3 trial of its novel anti-coagulant, Revolixys (previously … Continue Reading
Read now
